Loading company…
NES BIOTECHNOLOGY develops nanoparticle-based delivery kits for therapeutic nucleic acids, antibodies and proteins.
Founded in 2019 and based in Seoul, NES BIOTECHNOLOGY develops delivery kits for nucleic acids, antibodies and proteins intended for infectious diseases, cancer and hereditary diseases. Its gold nanoparticle system is designed to transport bioactive molecules into target cells. In July 2021, the company raised KRW 3 billion in venture funding from Genomictree, Inc. As of July 2023, Kangseok Lee was its CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in